Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

COL4A1 Gene Related Cerebra-retinal Angiopathy

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Assistance Publique - Hôpitaux de Paris
Sponsor:
Collaborator:
Ministry of Health, France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01097564
First received: February 19, 2010
Last updated: May 30, 2014
Last verified: April 2014
  Purpose

This prospective multicenter cohort study aims to define the clinical, radiological and mutational spectrum of the disease related to COL4A1 gene.


Condition Intervention
Cerebra-retinal Angiopathy
Genetic: COL4A1 genetic testing

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: COL4A1 Gene Related Cerebra-retinal Angiopathy : Clinical Spectrum From Children to Adult, Mutational Spectrum and Application to Routine Management of Affected Patients : a Prospective Cohort Study

Resource links provided by NLM:


Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Implication of COL4A1 gene (and other related genes) in intracranial haemorrhages of unknown etiology in children and young adults and in brain diffuse small vessel diseases of unknown etiology in young adults. [ Time Frame: at 36 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To define the whole clinical, radiological and mutational spectrum of COL4A1 gene. [ Time Frame: at 36 months ] [ Designated as safety issue: No ]
  • To define any genotype-phenotype correlation in COL4A1 gene disease. [ Time Frame: at 36 months ] [ Designated as safety issue: No ]
  • Application of the results in daily clinical practice [ Time Frame: at 36 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: February 2010
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
COL4A1 genetic testing
COL4A1 genetic testing
Genetic: COL4A1 genetic testing
genetic testing

Detailed Description:

150 index patients (children or young adult) and 100 relatives will be prospectively recruited over three years according to eligibility criteria. Clinical, brain MRI-MRA and genetic testing (COL4A1 mutation screening) will be conducted for each included patient or asymptomatic relatives. 13 French investigating centres will be participating to the study.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
  • patients children
  • patients young adult
  • family adult symptomatic
  • family adult asymptomatic
Criteria

Inclusion Criteria:

Inclusion criteria for the index patient :

  • Children and young adult (< 65 years)
  • Intracranial hemorrhage of unknown etiology
  • leukoencephalopathy
  • Any associated signs (including retinal arteriolar tortuosity, intracranial aneurysm, porencephaly, Infantile Cerebral Palsy, juvenile cataract)

Exclusion criteria:

(for the index patient)

  • Hypertension
  • Diabetes
  • Other (than COL4A1) genetic small vessel diseases of the brain
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01097564

Contacts
Contact: Hugues CHABRIAT, MD,PhD (33) 1 49 95 65 34 hugues.chabriat@lrb.aphp.fr
Contact: Elisabeth TOURNIER-LASSERVE, MD Phone : (33) 1 49 95 86 23 elisabeth.tournier@lrb.aphp.fr

Locations
France
Hôpital LARIBOISIERE Neurology Department Recruiting
Paris, France, 75010
Contact: Hugues CHABRIAT, MD,PhD    (33) 1 49 95 25 93    hugues.chabriat@lrb.aphp.fr   
Contact: Elisabeth TOURNIER-LASSERVE, MD,PhD    (33) 1 49 95 8623    elisabeth.tournier@lrb.aphp.fr   
Principal Investigator: Katayoun VAHEDI, MD         
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France
Investigators
Principal Investigator: Hugues CHABRIAT, MD,PhD Assistance Publique - Hôpitaux de Paris
  More Information

No publications provided

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT01097564     History of Changes
Other Study ID Numbers: P081214, 2009-A01163-54
Study First Received: February 19, 2010
Last Updated: May 30, 2014
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Genetic
Cerebral angiopathy
Retinal angiopathy
COL4A1 gene
Infantile Cerebral Palsy
Congenital porencephaly
Congenital cataract
Leukoencephalopathy
COL4A1 gene related cerebra-retinal angiopathy

ClinicalTrials.gov processed this record on November 20, 2014